OVAS

Ovascience, Inc.

A biotechnology company that developed fertility treatments for women, working with "egg precursor" cells found in the ovary and mitochondria to build procedures aimed at improving egg quality during IVF, such as AUGMENT, OvaPrime, and OvaTure. Founded in 2011 by a team including CEO Michelle Dipp and scientist Jonathan Tilly, its work challenged the long-held idea that women are born with a fixed number of eggs. The name blends "Ova" (Latin for egg) with "Science," and its AUGMENT treatment was offered in select international clinics but never in the United States.

No filing summaries or text available for this security.